NEOGENOMICS INC (NEO)
US64049M2098 - Common Stock
NEO Stock Earnings: NeoGenomics Beats EPS, Beats Revenue for Q1 2024
NEO stock results show that NeoGenomics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
NeoGenomics Reports First Quarter 2024 Results
NeoGenomics Announces Senior Leadership Promotions
NeoGenomics to Report First Quarter 2024 Financial Results on April 30, 2024
NeoGenomics Showcases Commitment to Transforming Cancer Patient Care at AACR 2024 Annual Meeting
NeoGenomics Releases Inaugural Environmental, Social, and Governance (ESG) Report
Commit To Purchase NeoGenomics At $10, Earn 9.1% Annualized Using Options
NeoGenomics to Participate in the TD Cowen 44th Annual Health Care Conference
NeoGenomics stock surged but technicals point to a pullback
NeoGenomics (NASDAQ: NEO) stock price popped sharply this week after the company published strong financial results. It soared to a high of $16.50, its highest point since December 29th. It has soared by more than 20% from its lowest point this week. Strong financial results NeoGenomics, a fast-growing company that offers cancer diagnostic and other […]
NeoGenomics shares jump after revenue forecast tops Street expectations (NASDAQ:NEO)
NeoGenomics shares rise over 9% as the cancer diagnostics firm forecasts annual revenue above estimates.
Why NeoGenomics Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Shares of NeoGenomics, Inc. (NASDAQ: NEO) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued FY24 adjusted EPS guidance above estimates.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to start the day with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Wednesday!
NeoGenomics Reports Fourth Quarter and Full Year 2023 Results
NeoGenomics Q4 2023 Earnings Preview (NASDAQ:NEO)
NeoGenomics is set to announce its Q4 earnings results, with a consensus EPS estimate of -$0.03 (+50.0% Y/Y) and a revenue estimate of $152.53M (+9.7% Y/Y).
NeoGenomics is Now Oversold (NEO)
NeoGenomics Signs Working with Cancer Pledge in Support of Employees
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NeoGenomics, Inc. - NEO
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ: NEO). Such...
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NYSE:BMY),(NYSE:TMO),(NASDAQ:NTRA),(NASDAQ:NEO) EQNX::TICKER_END
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
NeoGenomics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20, 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NeoGenomics, Inc. - NEO
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ: NEO). Such...
NeoGenomics Breaks Above 200-Day Moving Average - Bullish for NEO
Natera Hits A Nearly Two-Year High After Notching A Win In A Patent Battle
The company must pay $57 million in damages, but that's far less than expected.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NeoGenomics, Inc. - NEO
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ: NEO). Such...